Bromo‐ and extraterminal domain protein inhibition improves immunotherapy efficacy in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) represents the majority of liver cancer and is the fourth most common cause of cancer‐related death. Although advances in molecular targeted therapy have shown promise, none of these agents has yet demonstrated significant clinical benefit. Bromo‐ and extraterminal dom...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Sci
Egile Nagusiak: Liu, Chen, Miao, Xiaolong, Wang, Yao, Wen, Liang, Cheng, Xiawei, Kong, Deqiang, Zhao, Pengwei, Song, Dandan, Wang, Xinyi, Ding, Xianfeng, Xia, Hongguang, Wang, Weilin, Sun, Qiming, Gong, Weihua
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2020
Gaiak:
Basic and Clinical Immunology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7540980/
https://ncbi.nlm.nih.gov/pubmed/32726482
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14588
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak